Skip to main content
SpringerLink
Log in
Book cover

Modern Trends in Human Leukemia VIII pp 141–148Cite as

Use of Investigational Drugs as Initial Therapy for Childhood Solid Tumors

  • Conference paper

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 32))

Abstract

Solid tumors are relatively rare in children, but comprise about two-thirds of all malignancies that affect this age group. Most of these tumors respond well to initial treatment, and some (Wilms’ tumor, low-stage Hodgkin’s disease, low-stage rhabdomyosarcoma, and low-stage neuroblastoma) are readily cured with modern therapy. Still, many tumors that respond initially acquire clinical drug resistance, respond poorly to rechallenge with known active agents, and demonstrate a low level of responsiveness to experimental agents. This creates a major therapeutic dilemma for the pediatric oncologist. Although a critical need exists to identify new active agents for many solid tumors in childhood, current primary therapy is frequently quite active even in tumors which have a very high rate of relapse.

Supported in part by grants CA 23099 and CA 21765 from the National Cancer Institute and the American Lebanese Syrian Associated Charities (ALSAC)

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Horowitz ME, Etcubanas E, Christensen ML et al. (1988) Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anti-cancer drug development. J Clin Oncol 6: 308–314

    PubMed  CAS  Google Scholar 

  2. Houghton JA, Houghton PJ, Green AA (1982) Chemotherapy of childhood rhab-domyosarcoma growing as xenografts in immunedeprived mice. Cancer Res 42: 535–539

    PubMed  CAS  Google Scholar 

  3. Houghton J, Cook R, Lutz P, Houghton P (1985) L-Phenylalanine mustard (NSC 8806): a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 69: 91–96

    PubMed  CAS  Google Scholar 

  4. Magrath I, Sandlund J, Rayner A et al. (1985) Treatment of recurrent sarcomas with ifosfamide. Proc ASCO 4: 130

    Google Scholar 

  5. De Kraker J, Voute P (1984) Ifosfamide and vincristine in paediatric tumors: a phase II study. Eur Paediatr Haematol Oncol 1: 47–50

    Article  Google Scholar 

  6. Pratt CB, Horowitz ME, Meyer WH et al. (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71: 131–135

    PubMed  CAS  Google Scholar 

  7. Marti C, Kroner T, Remagen W et al. (1985) High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 69: 115–117

    PubMed  CAS  Google Scholar 

  8. Miser J, Kinsella T, Tsokos M et al. (1986) High response rate of recurrent childhood tumors to etoposide (VP-16), ifosfamide (IFOS) and mesna ( MES) uroprotection. Proc ASCO 5: 209

    Google Scholar 

  9. Green D, Jaffe N (1978) Progress and controversy in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 5: 7–27

    Article  CAS  Google Scholar 

  10. Maurer HM, Beltangady M, Gehan EA et al. (1988) The intergroup rhab-domyosarcoma study-I. A final report. Cancer 61: 209–220

    Article  PubMed  CAS  Google Scholar 

  11. Etcubanas E, Kun L, Pratt C et al. (1985) Patterns of failure in the treatment of childhood rhabdomyosarcoma: a review of prospective studies at St Jude Hospital. Proceedings of the XVIIth Meeting of the International Society for Pediatric Oncology, Sept 30-Oct 4 Venice, p 95 (abstr)

    Google Scholar 

  12. Horton JK, Houghton PJ, Houghton JA (1987) Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res 47: 6288–6293

    PubMed  CAS  Google Scholar 

  13. Bode U, Levine AS (1982) The biology and management of osteosarcoma. In: Levine AS (ed) Cancer in the young. Masson, New York

    Google Scholar 

  14. Link MP, Goorin AM, Miser AW et al. (1986) The effect of adjuvant chemotherapy on relapsefree survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 16010–1606

    Article  Google Scholar 

  15. Look AT, Douglass EC, Meyer WH (1988) Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity. N Engl J Med 318: 1567–1572

    Article  PubMed  CAS  Google Scholar 

  16. Liddell RHA, Meyer WH, Dodge RK, Green AA, Pratt CB (1988) Prognostic indicators for patients with osteosarcoma ( OS ). Proc Am Assoc Cancer Res 29: 226

    Google Scholar 

  17. Link MP, Shuster JJ, Goorin AM et al. (1988) Adjuvant chemotherapy in the treatment of osteosarcoma: results of the multi-institutional osteosarcoma study. In: Ryan JR, Baker LO (eds) Recent concepts in sarcoma treatment. Kluwer, Dordrecht, pp 283–290

    Chapter  Google Scholar 

  18. Meyer WH, Houghton JA, Houghton PJ et al. (1987) Development and characterization of pediatric osteosarcoma ( OS) xenografts. Proc Am Assoc Cancer Res 28: 430

    Google Scholar 

  19. Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced sub-clinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 71: 127–130

    PubMed  CAS  Google Scholar 

  20. Hayes FA, Thompson EI, Hustu HO et al. (1983) The response of Ewing’s sarcoma to sequential cyclophosphamide and Adriamycin induction therapy. J Clin Oncol 1: 45–51

    PubMed  CAS  Google Scholar 

  21. Pilepich MV, Vietti TJ, Nesbit ME et al. (1981) Radiotherapy and combination chemotherapy in advanced Ewing’s sarcoma-intergroup study. Cancer 47: 1930–1936

    Article  Google Scholar 

  22. Gobel V, Jiirgens H, Etspiiler G et al. (1987) Prognostic significance of tumor volume in localized Ewing’s sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 113: 187–191

    Article  PubMed  CAS  Google Scholar 

  23. Miser J, Kinsella T, Triche T et al. (1988) Treatment of recurrent sarcomas in children and young adults: the use of a multi-modality approach including ifosfamide (IFF) and etoposide (VP-16). Proc ASCO 7: 258

    Google Scholar 

  24. Bork E, Hansen M, Dombernowsky P et al. (1986) Teniposide (VM-26), an over-looked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 4: 524–527

    PubMed  CAS  Google Scholar 

  25. Cullen MH, Smith SR, Benfield GFA, Woodroffe CM (1987) Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease. Cancer Treat Rep 71: 1227–1230

    PubMed  CAS  Google Scholar 

  26. Cullen MH, Hilton C, Stuart NSA (1988) Evaluating new drugs as first treatment in patients with small-cell carcinoma: guidelines for an ethical approach with implication for other chemotherapy-sensitive tumors. J Clin Oncol 6: 1356–1357 (letter)

    Google Scholar 

  27. Kellie SJ, De Kraker J, Lilleyman J et al. (1987) Ifosfamide in previously untreated disseminated neuroblastoma: results of study 3 A of the European Neuroblastoma Study Group. Eur J Clin Oncol 24: 903–908

    Article  Google Scholar 

  28. De Kraker J, Pritchard J, Hartmann O, Ninane J (1987) Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG Study 2). Paediatr Hematol Oncol 4: 101–104

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Hematology-Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    W. H. Meyer, M. E. Horowitz, E. Etcubanas, C. B. Pratt, F. A. Hayes, E. I. Thompson, A. A. Green, J. T. Sandlund & W. M. Crist

  2. Department of Biochemical and Clinical Pharmacology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    P. J. Houghton & J. A. Houghton

  3. Department of Pediatrics, University of Tennessee, Memphis, College of Medicine, Memphis, TN, USA

    W. H. Meyer, M. E. Horowitz, E. Etcubanas, C. B. Pratt, F. A. Hayes, E. I. Thompson, A. A. Green, J. T. Sandlund & W. M. Crist

Authors
  1. W. H. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. J. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Etcubanas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. B. Pratt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. A. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. I. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. A. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. A. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. T. Sandlund
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. W. M. Crist
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik, Abteilung für klinische Chemie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 2000, Hamburg 20, Germany

    Rolf Neth

  2. Laboratory of Tumor Cell Biology, National Cancer Institute, 20892, Bethesda, MD, USA

    Robert C. Gallo

  3. Chester Beatty Laboratories, Leukemia Research Fund Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK

    Melvyn F. Greaves

  4. Abteilung Pädiatrie II, Universitätskinderklinik und Poliklinik Ulm, Prittwitzstr. 43, 7900, Ulm, Germany

    Gerhard Gaedicke

  5. Universität Ulm, Prittwitzstr. 43, 7900, Ulm, Germany

    Gerhard Gaedicke

  6. Labor für Hautimmunologie, Bioverträglichkeit-Immunologie, Paul-Gerson-Unna-Forschungszentrum, Beiersdorf-AG, Unnastr. 48, 2000, Hamburg 20, Germany

    Sven Gohla

  7. Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie, Martinistr. 52, 2000, Hamburg 20, Germany

    Klaus Mannweiler

  8. Abteilung Hämatologie und Onkologie, Kinderklinik und Poliklinik der Westfälischen Wilhelms-Universität, Albert-Schweitzer-Str. 33, 4400, Münster, Germany

    Jörg Ritter

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Meyer, W.H. et al. (1989). Use of Investigational Drugs as Initial Therapy for Childhood Solid Tumors. In: Neth, R., et al. Modern Trends in Human Leukemia VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 32. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74621-5_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74621-5_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50967-7

  • Online ISBN: 978-3-642-74621-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation